Skip to main content
SpringerLink
Log in

Infection-Related Hemolytic Uremic Syndrome (HUS)

  • Living reference work entry
  • First Online:
Pediatric Nephrology

  • 51 Accesses

Abstract

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) clinically defined by thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and acute kidney injury. HUS is categorized as infection-related HUS, typically caused by Shiga toxin producing Escherichia coli (STEC), rarely by Streptococcus pneumoniae, as atypical HUS (aHUS), or as secondary HUS with a coexisting systemic disease. Recent data indicated the involvement of the complement system in the pathogenesis of infectious agent-induced HUS as well. This chapter reviews current concepts of infection-related HUS in the point of view regarding the classification, epidemiological findings, pathophysiological and clinical aspects of STEC, Streptococcus pneumoniae, and other infectious agent-associated HUS, and their diagnosis and management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Reference

  1. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J [Internet]. 2019;12(3):333–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543965/pdf/sfz040.pdf

    Article  Google Scholar 

  2. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390:681–96.

    Article  PubMed  Google Scholar 

  3. Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, Paracchini V, Tel F, Possenti I, Belingheri M, Civitillo CF, Sardini S, Ceruti R, Baldioli C, Tommasi P, Parola F, Tedeschi S. Epidemiology of haemolytic uraemic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr. 2016;175:465–73.

    Article  CAS  PubMed  Google Scholar 

  4. Ashida A, Matsumura H, Sawai T, Fujimaru R, Fujii Y, Shirasu A, Nakakura H, Iijima K. Clinical features in a series of 258 Japanese pediatric patients with thrombotic microangiopathy. Clin Exp Nephrol. 2018;22:924–30.

    Article  PubMed  Google Scholar 

  5. Riley LW, Renis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen ML. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983;308:681–5.

    Article  CAS  PubMed  Google Scholar 

  6. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1(8325):619–20.

    Article  CAS  PubMed  Google Scholar 

  7. Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ, Yeung DH, Kirk MD. Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis. 2014;11:447–55.

    Article  PubMed  Google Scholar 

  8. CDC. National enteric disease surveillance: Shiga toxin-producing Escherichia coli (STEC) Annual Report, 2015. https://www.cdc.gov/nationalsurveillance/pdfs/STEC_Annual_Summary_2015-508c.pdf. Accessed 23 Oct 2020.

  9. ECDC ECDC surveillance report. Surveillance of seven priorities food-and waterborne diseases in the EU/EEA 2010–2012. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/food-and-waterborne-diseases-surveillance-report-2015.pdf. Accessed 23 Oct 2020.

  10. Morita-Ishihara T, Iyoda S, Iguchi A, Ohnishi M. Secondary Shiga toxin-producing Escherichia coli infection, Japan, 2010–2012. Emerg Infect Dis. 2016;22:2181–4.

    Article  PubMed  PubMed Central  Google Scholar 

  11. National Institute of Infection Disease and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare. Infectious agents surveillance report. 2020;41:65–88. https://www.niid.go.jp/niid/images/idsc/iasr/41/483.pdf. Accessed 23 Oct 2020.

  12. Bruyand M, Mariani-Kurkdjian P, Gouali M, Valk H, King LA, Hello SL, Bonacorsi S, Loirat C. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018;48:167–74.

    Article  CAS  PubMed  Google Scholar 

  13. Veesenmeyer AF, Edmonson MB. Trends in US hospital stays for streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J. 2013;32:731–5.

    Article  PubMed  Google Scholar 

  14. Bender JM, Ampofo K, Byington CL, Grinsell M, Korgenski K, Daly JA, Mason EO, Pavia AT. Epidemiology of streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children. Pediatr Infect Dis J. 2010;29:712–6.

    Article  PubMed  Google Scholar 

  15. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Active Bacterial Core Surveillance Team. Postvaccine genetic structure of streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–95.

    Article  CAS  PubMed  Google Scholar 

  16. Frank C, Werber D, Cramer JP, Askar M, Faber M, Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Müller L, King LA, Rosner B, Buchholz U, Stark K, Krause G. HUS investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771–80.

    Article  CAS  PubMed  Google Scholar 

  17. ECDC ECDC surveillance report. Surveillance of six priority food-and waterborne diseases in the EU/EEA 2006–2009. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/food-and-waterborne-diseases-surveillance-report.pdf. Accessed 21 Feb 2020.

  18. Jenkins C, Byrne L, Vishram B, Sawyer C, Balasegaram S, Ahyow L, et al. Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS): diagnosis, surveillance and public-health management in England [Internet]. J Med Microbiol Microbiol Soc. 2020;69:1034–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481745/.

    Article  Google Scholar 

  19. Adams NL, Byrne L, Smith GA, Elson R, Harris JP, Salmon R, Smith R, O’Brien SJ, Adak GK, Jenkins C. Shiga toxin-producing Escherichia coli O157, England and Wales, 1983–2012. Emerg Infect Dis. 2016;22:590–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Luna-Gierke RE, Griffin PM, Gould LH, Herman K, Bopp CA, Strockbine N, Mody RK. Outbreaks of non-O157 Shiga toxin-producing Escherichia coli infection: USA. Epidemiol Infect. 2014;142:2270–80.

    Article  CAS  PubMed  Google Scholar 

  21. Kintz E, Braubard J, Hooper L, Hunter P. Transmission pathways for sporadic Shiga-toxin producing E. coli infections: a systematic review and meta-analysis. Int J Hyg Environ Health. 2017;220:57–67.

    Article  PubMed  Google Scholar 

  22. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins. 2010;2:2769–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yang X, Bai X, Zhang J, Sun H, Fu S, Fan R, He X, Scheutz F, Matussek A, Xiong Y. Escherichia coli strains producing a novel Shiga toxin 2 subtype circulate in China. Int J Med Microbiol. 2020;310:151377.

    Article  CAS  PubMed  Google Scholar 

  24. Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, Strockbine NA, Melton-Celsa AR, Sanchez M, Person S, O’Brien AD. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol. 2012;50:2951–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kavanagh D, Sheerin N. Thrombotic microangiopathy. In: Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW, editors. Brenner & Rector’s the kidney. 11th ed. Philadelphia: Elsevier; 2020. p. 1178–95.

    Google Scholar 

  26. Keir LS, Marks SD, Kim JJ. Shiga toxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther. 2012;6:195–208.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Petruzziello-Pellegrini TN, Yuen DA, Page AV, Patel S, Soltyk AM, Matouk CC, Wong DK, Turgeon PJ, Fish JE, Ho JJD, Steer BM, Khajoee V, Tigdi J, Lee WL, Motto DG, Advani A, Gilbert RE, Karumanchi SA, Robinson LA, Tarr PI, Liles C, Brunton JL. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest. 2012;122:759–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005;106:4199–209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest. 1998;101:372–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun. 1993;61:3886–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B, Tobin-D’Angelo M, Smith G, Spina N, Hurd S, Lathrop S, Palmer A, Boothe E, Luna-Gierke RE, Hoekstra RM. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr. 2015;166:1022–9.

    Article  PubMed  Google Scholar 

  32. Exeni RA, Fernandez-Brando RJF, Santiago AP, Fiorentino GA, Exeni AM, Ramos MV, Palermo MS. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2018;33:2057–71.

    Article  PubMed  Google Scholar 

  33. Gomez SA, Abrey-Recalde MJ, Panek CA, Ferrarotti NF, Repetto MG, Mejias MP, Fernandez GC, Vanzulli S, Isturiz MA, Palermo MS. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol. 2013;173:463–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ferraris V, Acquier A, Ferraris JR, Vallejo G, Paz C, Mendez CF. Oxidative stress during the acute phase of haemolytic uraemic syndrome. Nephrol Dial Transplant. 2011;26:858–64.

    Article  CAS  PubMed  Google Scholar 

  35. Aiassa V, Baronetti JL, Paez PL, Bames AI, Albrecht C, Pellarin G, Eraso AJ, Albesa I. Increased advanced oxidation of protein products and enhanced total antioxidant capacity in plasma by action of toxins of Escherichia coli STEC. Toxicol In Vitro. 2011;25:426–31.

    Article  CAS  PubMed  Google Scholar 

  36. Facorro G, Aguirre F, Florentin L, Díaz M, Poli TD, Ihlo JE, Hager AA, Avalos JCS, Farach HA, Poole CP Jr. Oxidative stress and membrane fluidity in erythrocytes from patients with hemolytic uremic syndrome. Acta Physiol Pharmacol Ther Latinoam. 1997;47:137–46.

    CAS  PubMed  Google Scholar 

  37. Robson WL, Leung AK, Fick GH, McKenna AI. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron. 1992;62:296–9.

    Article  CAS  PubMed  Google Scholar 

  38. Thuman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1920–4.

    Article  CAS  Google Scholar 

  39. Awofisayo-Okuyelu A, Brainard J, Hall I, McCarthy N. Incubation period of Shiga toxin-producing Escherichia coli. Epidemiolo Rev. 2019;41:121–9.

    Article  Google Scholar 

  40. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86.

    CAS  PubMed  Google Scholar 

  41. Shigeno T, Akamatsu T, Fujimori K, Nakatsuji Y, Nagata A. The clinical significance of colonoscopy in hemorrhagic colitis due to enterohemorrhagic Escherichia coli O157:H7 infection. Endoscopy. 2002;34:311–4.

    Article  CAS  PubMed  Google Scholar 

  42. Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M. Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol. 2014;18:525–57.

    Google Scholar 

  43. Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8:658–69.

    Article  CAS  PubMed  Google Scholar 

  44. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186:493–500.

    Article  PubMed  Google Scholar 

  45. Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX. Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care. 2005;28:2556–662.

    Article  PubMed  Google Scholar 

  46. Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, German-Austrian HUS Study Group. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.

    Article  PubMed  Google Scholar 

  47. Rahman RC, Coben CJ, Drut R, Amoreo OR, Ruscasso JD, Spizzirri AP, Suarez ADC, Zalba JH, Ferrari C, Gatti MC. Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol. 2012;27:229–33.

    Article  PubMed  Google Scholar 

  48. Békássy ZD, Toledo CC, Leoj G, Kristoffersson A, Leopold SR, Perez MT, Karpman D. Intestinal damage in enterohemorrhagic Escherichia coli infection. Pediatr Nephrol. 2011;26:2059–71.

    Article  PubMed  Google Scholar 

  49. Matsumoto K, Nishimoto Y, Taguchi T, Tsutsumi Y, Kanemitsu S, Hara T, Suita S. Colonic stricture secondary to hemolytic uremic syndrome caused by Escherichia coli O157. Pediatr Nephrol. 2005;20:1496–9.

    Article  Google Scholar 

  50. Roessingh ASB, Lagausie P, Baudoin V, Loirat C, Aigrain Y. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg. 2007;17:328–34.

    Article  Google Scholar 

  51. Whitington PF, Friedman AL, Chesney RW. Gastrointestinal disease in the hemolytic uremic syndrome. Gastroenterology. 1979;76:728–33.

    Article  CAS  PubMed  Google Scholar 

  52. Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhea-associated haemolytic uraemic syndrome. Pediatr Nephrol. 1995;9:117–9.

    Article  CAS  PubMed  Google Scholar 

  53. Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Vaterodt L, et al. Short- and long-term renal outcome of hemolytic-uremic syndrome in childhood. Front Pediatr. 2018;6:220.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child [Internet]. 2018;103(3):285–91. https://doi.org/10.1136/archdischild-2016-311377.

    Article  Google Scholar 

  56. Wurzner R, Riedl M, Rosales A, Orth-Holler D. Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS). Semin Thromb Hemost [Internet]. 2014;40(4):508–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24802085

    Article  CAS  Google Scholar 

  57. Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005;115:e673–80.

    Article  PubMed  Google Scholar 

  58. Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castrina P, Bolsa-Ghiringhlli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G. Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol. 2015;30:345–52.

    Article  PubMed  Google Scholar 

  59. Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Bolsa-Ghiringhlli N, Salice P, Tedeschi S, Castrina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016:137. https://doi.org/10.1542/peds.2015-2153.

  60. Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011;165:884–9.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Grisaru S, Xie J, Samuel S, Hartling L, Tarr PI, Schnadower D, Freedman SB, Alberta Provincial Pediatric Enteric Infection Team. Association between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:68–76.

    Article  PubMed  Google Scholar 

  62. Weil BR, Andreoli SP, Billmire DF. Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol. 2010;25(9):1693–8. https://doi.org/10.1007/s00467-010-1530-1. Epub 2010 Apr 27. PMID: 20422224.

    Article  PubMed  Google Scholar 

  63. Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol [Internet]. 2013;28(6):919–25. Available from: https://pubmed.ncbi.nlm.nih.gov/23386110/

    Article  Google Scholar 

  64. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant [Internet]. 2012;27(10):3807–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23114903

    Article  CAS  Google Scholar 

  65. Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI. Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis [Internet]. 2016;62(10):1251–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26917812/

    Article  Google Scholar 

  66. Kakoullis L, Papachristodoulou E, Chra P, Panos G. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview [Internet]. J Infect. W.B. Saunders Ltd. 2019;79:75–94. Available from: https://pubmed.ncbi.nlm.nih.gov/31150744/

    Google Scholar 

  67. Mühlen S, Dersch P. Treatment strategies for infections with shiga toxin-producing Escherichia coli. Front Cell Infect Microbiol [Internet]. 2020;10:169. Available from: www.frontiersin.org

    Article  CAS  Google Scholar 

  68. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DWK, et al. Effect of an Oral Shiga Toxin-Binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA [Internet]. 2003;290:1337.

    Article  CAS  Google Scholar 

  69. Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli [Internet]. Arch Immunologiae et Therapiae Experimentalis. Arch Immunol Ther Exp (Warsz). 2011;59:239–47. Available from: https://pubmed.ncbi.nlm.nih.gov/21644029/

    Article  CAS  Google Scholar 

  70. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol [Internet]. 2012;8(11):622–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22986360

    Article  CAS  Google Scholar 

  71. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med [Internet]. 2009;360(5):542–4. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19179328

    Article  Google Scholar 

  72. Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med [Internet]. 2011;364(26):2561–3. https://doi.org/10.1056/NEJMc1100859.

    Article  CAS  Google Scholar 

  73. Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine. 2015;94(24)

    Google Scholar 

  74. Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome [Internet]. Pediatr Nephrol Springer. 2019;34:1485–92. https://doi.org/10.1007/s00467-018-4025-0.

    Article  Google Scholar 

  75. Huang DT, et al. T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia. Pediatr Infect Dis J. 2006;25(7):608–10.

    Article  PubMed  Google Scholar 

  76. Singh AK, et al. Defining the role of pneumococcal neuraminidases and O-glycosidase in pneumococcal haemolytic uraemic syndrome. J Med Microbiol. 2016;65(9):975–84.

    Article  CAS  PubMed  Google Scholar 

  77. Janapatla RP, et al. Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children. Clin Microbiol Infect. 2013;19(5):480–6.

    Article  CAS  PubMed  Google Scholar 

  78. Klein PJ, et al. Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet. 1977;2(8046):1024–5.

    Article  CAS  PubMed  Google Scholar 

  79. Loupiac A, et al. Diagnosis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J. 2013;32(10):1045–9.

    Article  PubMed  Google Scholar 

  80. Copelovitch L, Kaplan BS. Streptococcus pneumoniae – associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics. 2010;125(1):e174–82.

    Article  PubMed  Google Scholar 

  81. von Vigier RO, et al. Positive Coombs test in postpneumococcal hemolytic-uremic syndrome. Pediatr Infect Dis J. 2005;24(11):1028–9.

    Article  Google Scholar 

  82. Chen YC, et al. Thomsen-Friedenreich antigen activation as a predictor for clinical outcome of pediatric patients with invasive pneumococcal disease. Pediatr Neonatol. 2020;61(3):338–42.

    Article  PubMed  Google Scholar 

  83. Meinel C, et al. Streptococcus pneumoniae from patients with hemolytic uremic syndrome binds human plasminogen via the surface protein PspC and uses plasmin to damage human endothelial cells. J Infect Dis. 2018;217(3):358–70.

    Article  CAS  PubMed  Google Scholar 

  84. Ahmad N, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 2004;279(12):10841–7.

    Article  CAS  PubMed  Google Scholar 

  85. Burin des Roziers N, et al. Red blood cell Thomsen-Friedenreich antigen expression and galectin-3 plasma concentrations in Streptococcus pneumoniae-associated hemolytic uremic syndrome and hemolytic anemia. Transfusion. 2015;55(6 Pt 2):1563–71.

    Article  CAS  PubMed  Google Scholar 

  86. Brown EJ, Joiner KA, Frank MM. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. J Clin Invest. 1983;71(6):1710–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Brown EJ, et al. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. J Immunol. 1983;131(1):409–15.

    CAS  PubMed  Google Scholar 

  88. Fearon DT. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA. 1978;75(4):1971–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Kerr H, et al. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem. 2017;292(32):13345–60.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Bitzan M, et al. Complement depletion and coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. Int J Med Microbiol. 2018;308(8):1096–104.

    Article  CAS  PubMed  Google Scholar 

  91. Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses. 2013;81(3):400–3.

    Article  CAS  PubMed  Google Scholar 

  92. Szilagyi A, et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2013;28(9):2237–45.

    Article  CAS  PubMed  Google Scholar 

  93. Spinale JM, et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013;25(2):203–8.

    Article  CAS  PubMed  Google Scholar 

  94. Waters AM, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr. 2007;151(2):140–4.

    Article  PubMed  Google Scholar 

  95. Banerjee R, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J. 2011;30(9):736–9.

    Article  PubMed  Google Scholar 

  96. Kaczmarek V, et al. Caplacizumab for relapsing thrombotic thrombocytopenic purpura. Pediatr Nephrol. 2019;34(9):1625–8.

    Article  PubMed  Google Scholar 

  97. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AK. Shigellosis. Lancet. 2018;391:801–82.

    Article  PubMed  Google Scholar 

  98. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Plats-Mills JA, Qadri F, Riddle MS, Ryan ET, Shoultz DA, Steele AD, Walson JL, Sanders JW, Mokdad AH, Murray CJL, Hay SI, Reiner RC Jr. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990–2016. Lancet Infect Dis. 2018;18:1229–40.

    Article  PubMed  PubMed Central  Google Scholar 

  99. CDC. National enteric disease surveillance: Shigella annual report, 2016. https://www.cdc.gov/nationalsurveillance/pdfs/LEDS-Shig-2016-REPORT-508.pdf Accessed 21 Feb 2021.

  100. Rahaman MM, Alam AKMJ, Islam MR, Greenough WB, Lindenbaum J. Shiga bacillus dysentery associated with marked leukocytosis and erythrocyte fragmentation. Johns Hopkins Med J. 1975;136:65–70.

    CAS  PubMed  Google Scholar 

  101. Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg. 2012;106:395–9.

    Article  PubMed  Google Scholar 

  102. Taylor CM. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008;23:1425–31.

    Article  Google Scholar 

  103. Bennish ML, Khan WA, Begum M, Bridges EA, Ahmed S, Saha D, Salam MA, Acheson D, Ryan ET. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis. 2006;42:356–62.

    Article  CAS  PubMed  Google Scholar 

  104. Petersen VP, Olsen TS. Late renal transplant failure due to the hemolytic-uremic syndrome. Acta Med Scand. 1971;189:377–80.

    Article  CAS  PubMed  Google Scholar 

  105. Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol. 2018;33:2009–25.

    Article  PubMed  Google Scholar 

  106. Armstrong SM, Darwish I, Lee WL. Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection. Virulence. 2013;4:537–42.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Berdal JE, Mollnes TE, Wæhre T, Oltad OK, Halvorsen B, Ueland T, Laake JH, Furuseth MT, Maagaard A, Kjejshus H, Aukrust P, Jonassen CM. Excessive innate immune response and mutant D222G/N in severe A (H1N1) pandemic influenza. J Infect. 2011;63:308–16.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tokushima University Hospital, Tokushima, Japan

    Shoji Kagami

  2. Department of pediatric Gastroenterology, Nephrology and Metabolic Disorders, Charité, Berlin, Germany

    Müller Dominik

  3. National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

    Michal Malina

  4. First Faculty of Medicine, Charles University, Prague, Czech Republic

    Michal Malina

  5. Department of Pediatrics, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan

    Akira Ashida

Authors
  1. Shoji Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Müller Dominik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michal Malina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Ashida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shoji Kagami .

Editor information

Editors and Affiliations

  1. Division of Nephrology, Bambino Gesù Children’s Hospital –, ROMA, Roma, Italy

    Francesco Emma

  2. Division of Nephrology and Hypertension The Heart Institute, University of Cincinnati Cincinnati Children’s Hospital Medical C, Cincinnati, OH, USA

    Stuart Goldstein

  3. Division of Nephrology, All India Institute of Medical Sciences, Ansari Nagar East, Delhi, India

    Arvind Bagga

  4. Division of Pediatric Nephrology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Carlton M. Bates

  5. Renal Unit, Graet Ormond Street Hospital, London, UK

    Rukshana Shroff

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Germany, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kagami, S., Dominik, M., Malina, M., Ashida, A. (2021). Infection-Related Hemolytic Uremic Syndrome (HUS). In: Emma, F., Goldstein, S., Bagga, A., Bates, C.M., Shroff, R. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27843-3_99-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27843-3_99-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-27843-3

  • Online ISBN: 978-3-642-27843-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation